PURPOSE: Despite the comparably high cure rates observed for HPV-positive HNSCC, there is still a great need for specific tumor radiosensitization due to the often severe side effects resulting from intense radiochemotherapy. We recently demonstrated that HPV-positive HNSCC cell lines are characterized by a defect in DNA double-strand break repair associated with a pronounced G2-arrest. Here we tested whether abrogation of this radiation-induced G2-arrest by the inhibition of Chk1 results in specific radiosensitization of HPV-positive HNSCC cells. MATERIALS AND METHODS: Experiments were performed with five HPV and p16-positive (93-VU-147T, UM-SCC-47, UT-SCC-45, UD-SCC-2, UPCI-SCC-154) and two HPV and p16-negative HNSCC cell lines, as well as two normal human fibroblast strains. Chk1 was inhibited by the selective inhibitor PF-00477736. Cell cycle distribution was determined by flow cytometry, Chk1-activity via Western blot and cell survival by colony formation assay. RESULTS: With the exception of UPCI-SCC-154, the inhibition of Chk1 was found to abolish the pronounced radiation-induced G2-arrest in all HPV-positive cells utilized. All tumor cell lines that demonstrated the abrogation of G2-arrest also demonstrated radiosensitization. Notably, in G1-arrest-proficient normal human fibroblasts no radiosensitization was induced. CONCLUSION: Abrogation of the G2 checkpoint through the inhibition of Chk1 may be used to selectively increase the cellular radiosensitivity of HPV-positive HNSCC without affecting the surrounding normal tissue.
PURPOSE: Despite the comparably high cure rates observed for HPV-positive HNSCC, there is still a great need for specific tumor radiosensitization due to the often severe side effects resulting from intense radiochemotherapy. We recently demonstrated that HPV-positive HNSCC cell lines are characterized by a defect in DNA double-strand break repair associated with a pronounced G2-arrest. Here we tested whether abrogation of this radiation-induced G2-arrest by the inhibition of Chk1 results in specific radiosensitization of HPV-positive HNSCC cells. MATERIALS AND METHODS: Experiments were performed with five HPV and p16-positive (93-VU-147T, UM-SCC-47, UT-SCC-45, UD-SCC-2, UPCI-SCC-154) and two HPV and p16-negative HNSCC cell lines, as well as two normal human fibroblast strains. Chk1 was inhibited by the selective inhibitor PF-00477736. Cell cycle distribution was determined by flow cytometry, Chk1-activity via Western blot and cell survival by colony formation assay. RESULTS: With the exception of UPCI-SCC-154, the inhibition of Chk1 was found to abolish the pronounced radiation-induced G2-arrest in all HPV-positive cells utilized. All tumor cell lines that demonstrated the abrogation of G2-arrest also demonstrated radiosensitization. Notably, in G1-arrest-proficient normal human fibroblasts no radiosensitization was induced. CONCLUSION: Abrogation of the G2 checkpoint through the inhibition of Chk1 may be used to selectively increase the cellular radiosensitivity of HPV-positive HNSCC without affecting the surrounding normal tissue.
Authors: Roy Xiao; Yi An; Wenda Ye; Adeeb Derakhshan; Hui Cheng; Xinping Yang; Clint Allen; Zhong Chen; Nicole C Schmitt; Carter Van Waes Journal: Clin Cancer Res Date: 2019-07-02 Impact factor: 12.531
Authors: Jessica M Molkentine; David P Molkentine; Kathleen A Bridges; Tongxin Xie; Liangpeng Yang; Aakash Sheth; Timothy P Heffernan; David A Clump; Alma Z Faust; Robert L Ferris; Jeffrey N Myers; Mitchell J Frederick; Kathryn A Mason; Raymond E Meyn; Curtis R Pickering; Heath D Skinner Journal: Int J Radiat Biol Date: 2020-02-25 Impact factor: 2.694
Authors: Michael T Spiotto; Cullen M Taniguchi; Ann H Klopp; Lauren E Colbert; Steven H Lin; Li Wang; Mitchell J Frederick; Abdullah A Osman; Curtis R Pickering; Steven J Frank Journal: Semin Radiat Oncol Date: 2021-10 Impact factor: 5.421
Authors: David P Molkentine; Jessica M Molkentine; Kathleen A Bridges; David R Valdecanas; Annika Dhawan; Reshub Bahri; Andrew J Hefner; Manish Kumar; Liangpeng Yang; Mohamed Abdelhakiem; Phillip M Pifer; Vlad Sandulache; Aakash Sheth; Beth M Beadle; Howard D Thames; Kathryn A Mason; Curtis R Pickering; Raymond E Meyn; Heath D Skinner Journal: Cancer Res Date: 2022-03-01 Impact factor: 13.312
Authors: Kathleen A Bridges; Xingxing Chen; Huifeng Liu; Crosby Rock; Thomas A Buchholz; Stuart D Shumway; Heath D Skinner; Raymond E Meyn Journal: Oncotarget Date: 2016-11-01